Cancer Cachexia Market Size & Share, by Drugs (Progestogens, Dronabinol, Mega Sterol Acetate, Corticosteroids); Mode of Action (Weight Loss Stabilizers, Appetite Stimulants); Indication (Cancer, CHF, Rheumatoid Arthritis, Chronic Kidney Disease, Cystic Fibrosis, COPD); Route Of Administration (Oral, Parenteral); Dosage Form (Tablets, Injections); Distribution Channel (Hospital, Retail & Online Pharmacy) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5372
  • Published Date: Nov 14, 2023
  • Report Format: PDF, PPT

Companies Dominating the Cancer Cachexia Market

top-features-companies
    • Pfizer, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Veru Inc.
    • Eli Lilly and Company
    • Bristol-Myers Squibb Company
    • Mylan N.V.
    • ANI Pharmaceuticals
    • Novartis AG
    • Hikma Pharmaceuticals Plc.
    • Sun Pharmaceutical Industries Ltd.
    • Teva Pharmaceutical Industries Ltd.

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer, today announced that it has entered into a clinical trial collaboration and supply agreement with Eli Lilly and Company. The objective of the collaboration is to evaluate the efficacy and safety of enobosarm, Veru’s oral, first-in-class, new chemical entity, selective androgen receptor targeting agonist that activates the androgen receptor (AR), a tumor suppressor, in combination with Lilly’s Verzenio (abemaciclib), a CDK4/6 inhibitor, as a second line therapy in the treatment of AR+ER+HER2- metastatic breast cancer.
  • Bristol-Myers Squibb Company successfully acquired Celgene Corporation to create a strong biopharma company. As per the officials of Bristol, its expertise in the fields of cardiovascular disease, hematology, immunology, and oncology would aid in transforming the lives of the patients through technological advancements.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 5372
  • Published Date: Nov 14, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing prevalence of chronic diseases, drug launches, research and development are the major factors driving the growth of the cancer cachexia market.

The market size of cancer cachexia is anticipated to attain a CAGR of 4.5% over the forecast period, i.e., 2024-2036.

The major players in the market are Veru, Inc, Eli Lilly and company, Bristol-Myers Squibb Company, Mylan N.V., ANI Pharmaceuticals, Novartis AG, Hikma Pharmaceuticals Plc., Sun pharmaceutical Industries Ltd., and others.

The weight loss stabilizers segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North America region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying